Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
Carl M. Gay, C. Allison Stewart, Elizabeth M. Park, Lixia Diao, Sarah M. Groves, Simon Heeke, Barzin Y. Nabet, Junya Fujimoto, Luisa M. Solis, Wei Lü, Yuanxin Xi, Robert J. Cardnell, Qi Wang, Giulia Fabbri, Kasey R. Cargill, Natalie I. Vokes, Kavya Ramkumar, Bingnan Zhang, Carminia Maria Della Corte, Paul Robson, Stephen G. Swisher, Jack A. Roth, Bonnie S. Glisson, David S. Shames, Ignacio I. Wistuba, Jing Wang, Vito Quaranta, John D. Minna, John V. Heymach, Lauren A. Byers
Topics & Concepts
Transcription factorCancer researchImmunotherapyBiologyCisplatinChemotherapyTranscription (linguistics)Immune systemOncologyMedicineImmunologyGeneGeneticsLinguisticsPhilosophyLung Cancer Research StudiesNeuroendocrine Tumor Research AdvancesChromatin Remodeling and Cancer